MRD Status Linked to Time to Next Treatment in MM
Patients with sustained minimal residual disease negativity had longer time to next treatment, regardless of baseline risk characteristics.
Diagnosis & Disease Information
Infections Observed in Half of MM Patients Treated With Bispecific Antibodies
Infections are common among patients with relapsed/refractory multiple myeloma treated with bispecific antibodies, a study suggests.
Anti-GPRC5D CAR-T Therapy Elicits Responses After Anti-BCMA CAR Failure
Anti-GPRC5D CAR T-cell therapy can produce responses in patients with relapsed or refractory multiple myeloma, a phase 2 trial suggests.
5 Factors That May Affect Multiple Myeloma Outcomes
What are some of the most important factors affecting outcomes in patients with multiple myeloma?
Second Primary Malignancies After Auto-HSCT Linked to Inferior Outcomes in MM
Multiple myeloma patients who develop second primary malignancies after auto-HSCT have worse survival outcomes, a study suggests.
Factors Linked to Worse CAR-T Outcomes in High-Risk Multiple Myeloma
High-risk cytogenetics and extramedullary disease may be associated with worse survival outcomes of CAR T-cell therapy in relapsed or refractory multiple myeloma, a meta-analysis suggests.
Elranatamab Under Review for Relapsed or Refractory Multiple Myeloma
The FDA has accepted for priority review the biologics license application for elranatamab to be used as a treatment for patients with relapsed or refractory multiple myeloma.
Pano/GBM Plus ASCT Deemed Safe and Effective in High-Risk or Rel/Ref MM
Pano/GBM is safe and effective as conditioning before ASCT in patients with high-risk or relapsed/refractory multiple myeloma, a study suggests.
Ide-Cel Bests Standard Care in Relapsed/Refractory Multiple Myeloma
Ide-cel improves outcomes in patients with triple-class-exposed multiple myeloma, when compared with standard care, a phase 3 trial suggests.
Patients With Double-Hit Multiple Myeloma Have Inferior Outcomes After Transplant
The presence of 2 or more cytogenetic risk markers is associated with inferior outcomes after transplant in patients with multiple myeloma.
- Loading...
Loading...
Next post in Multiple Myeloma
Loading... 
Loading...